WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018065622) IMMUNOSUPPRESSION-REVERTING OLIGONUCLEOTIDES INHIBITING THE EXPRESSION OF CD39
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/065622    International Application No.:    PCT/EP2017/075647
Publication Date: 12.04.2018 International Filing Date: 09.10.2017
IPC:
C12N 15/113 (2010.01), A61K 31/712 (2006.01), A61K 31/7125 (2006.01), C07H 21/00 (2006.01)
Applicants: SECARNA PHARMACEUTICALS GMBH & CO KG [DE/DE]; Bismarckstr. 7 35037 Marburg (DE)
Inventors: JASCHINSKI, Frank; (DE).
HILMENYUK, Tamara; (DE)
Agent: JANSEN, C.M.; (NL)
Priority Data:
16192807.2 07.10.2016 EP
17187774.9 24.08.2017 EP
Title (EN) IMMUNOSUPPRESSION-REVERTING OLIGONUCLEOTIDES INHIBITING THE EXPRESSION OF CD39
(FR) OLIGONUCLÉOTIDES D'INVERSION DE L'IMMUNOSUPPRESSION INHIBANT L'EXPRESSION DE CD39
Abstract: front page image
(EN)The present invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of an ectonucleotidase (NTPdase; CD73) of SEQ ID NO.1 (human), wherein the oligonucleotide inhibits at least 50 % of the CD39 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
(FR)La présente invention concerne des oligonucléotides d'inversion de l'immunosuppression comprenant 12 à 18 nucléotides, au moins l'un desdits nucléotides étant modifié, et l'oligonucléotide s'hybridant avec une séquence d'acide nucléique d'une ectonucléotidase (NTPdase; CD73) de SEQ ID NO.1 (origine humaine), l'oligonucléotide inhibant au moins 50 % de l'expression de CD39. L'invention concerne en outre une composition pharmaceutique comprenant un tel oligonucléotide.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)